Skip to content
Business websites
Business websites
J&J Innovative Medicine
J&J MedTech
J&J Innovative Medicine
Business websites
JNJ.com
NewPharm.com
JnJMedTech.com
J&J MedTech
US • English
Choose your country or region
China
中国人
France
Français
India
English
Japan
日本
Switzerland
Deutsch
Switzerland
English
Switzerland
Français
US
English
United Kingdom
English
Latest News
Back
Innovation
Caring & giving
Personal stories
Health & wellness
Our heritage
Our Company
Back
Discover J&J
Back
Our Credo
Our Leadership
Code of Business Conduct
Corporate Reports
Diversity, Equity & Inclusion
ESG Policies & Positions
Innovation at J&J
Digital Solutions
J&J Health & Wellness Solutions
Office of the Chief Medical Officer
Veterans, Military & Military Families
Innovative Medicine
MedTech
Our societal impact
Back
Global Health Equity
Global environmental sustainability
Suppliers
Back
Responsible Supply Base
Supplier Enabled Innovation
Supplier Resources
Careers
Back
Life at J&J
Diversity, Equity and Inclusion
Career Areas of Impact
Students
Re-Ignite Program
Contract & Freelance Partner Opportunities
Career Stories
Investors
Back
Pharmaceutical pipeline
ESG resources
Investor fact sheet
Media Center
Latest News
Back
Innovation
Caring & giving
Personal stories
Health & wellness
Our heritage
Our Company
Back
Discover J&J
Back
Our Credo
Our Leadership
Code of Business Conduct
Corporate Reports
Diversity, Equity & Inclusion
ESG Policies & Positions
Innovation at J&J
Digital Solutions
J&J Health & Wellness Solutions
Office of the Chief Medical Officer
Veterans, Military & Military Families
Innovative Medicine
MedTech
Our societal impact
Back
Global Health Equity
Global environmental sustainability
Suppliers
Back
Responsible Supply Base
Supplier Enabled Innovation
Supplier Resources
Careers
Back
Life at J&J
Diversity, Equity and Inclusion
Career Areas of Impact
Students
Re-Ignite Program
Contract & Freelance Partner Opportunities
Career Stories
Investors
Back
Pharmaceutical pipeline
ESG resources
Investor fact sheet
Media Center
Search Query
Submit Search
Dictate search request
Recently Viewed
Listening...
Show Search
Menu
Home
/
Media Center
/
Press releases
Press releases
Press Releases
Search Query
Submit Search
Dictate search request
Listening...
1,925 Results
Date
All Dates (1925)
Past 30 days (14)
2023 (140)
2022 (125)
2021 (185)
2020 (110)
2019 (130)
2018 (166)
2017 (196)
2016 (125)
Topic
All (1925)
Corporate (131)
ESG (1)
Financial (282)
Global Health Equity (59)
Leadership (20)
Medical technologies (257)
Pharmaceuticals (859)
Research (42)
1,925 results
Filters
Date
All Dates (1925)
Past 30 days (14)
2023 (140)
2022 (125)
2021 (185)
2020 (110)
2019 (130)
2018 (166)
2017 (196)
2016 (125)
Topic
All (1925)
Corporate (131)
ESG (1)
Financial (282)
Global Health Equity (59)
Leadership (20)
Medical technologies (257)
Pharmaceuticals (859)
Research (42)
Sort By:
Newest
Newest
Relevance
Oldest
April 16, 2024
Johnson & Johnson Announces 62nd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.2%
Read more
April 16, 2024
Johnson & Johnson Reports Q1 2024 Results
2024 First-Quarter reported sales growth of 2.3% to $21.4 Billion with operational growth of 3.9%* and adjusted operational growth of 4.0%* · Adjusted operational growth excluding COVID-19 Vaccine of 7.7%* 2024 First-Quarter Earnings per share (EPS) increased to $2.20 and adjusted EPS increased to $2.71 or 12.4%* Company increasing the midpoint for Full-Year 2024 operational sales5 and adjusted operational EPS guidance
Read more
April 11, 2024
Unique molecular properties of nipocalimab enabling differentiated potential in treating generalized myasthenia gravis to be presented at American Academy of Neurology’s 2024 Annual Meeting
Analysis of clinical and non-clinical studies supports the investigational treatment’s potential for rapid, deep and sustained immunoglobulin G (IgG) lowering
Read more
April 8, 2024
Johnson & Johnson to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
Read more
April 8, 2024
Findings Presented at ACC.24 Showed XARELTO® (rivaroxaban) Reduced the Risk of Clinically Significant Bleeding and Net Adverse Clinical Events or Rehospitalization
New exploratory analysis demonstrates consistent results of XARELTO® in treating elderly and non-elderly patients with nonvalvular atrial fibrillation undergoing percutaneous coronary intervention XARELTO® is one of the most studied oral anticoagulants, and has been prescribed to more than 10 million patients in the United States
Read more
April 6, 2024
CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy
Expanded indication for this one-time infusion will provide more patients with a potential period away from their multiple myeloma treatment as early as first relapse Approval is based on results from the Phase 3 CARTITUDE-4 study, in which treatment with CARVYKTI® in 1-3 prior lines of therapy reduced the risk of disease progression or death by 59 percent compared to standard therapies
Read more
April 5, 2024
Johnson & Johnson to Acquire Shockwave Medical
Enhances Johnson & Johnson’s Ability to Transform the Treatment Landscape for Cardiovascular Disease and Continue to Improve Patient Outcomes Extends Johnson & Johnson MedTech’s Position in Highest-Growth, Innovation-Oriented Segments of Cardiovascular Intervention Accelerates Sales Growth and Accretive to Operating Margin for Both Johnson & Johnson and Johnson & Johnson MedTech Conference Call at 8:30 a.m. ET To Discuss Details of the Transaction
Read more
April 4, 2024
Johnson & Johnson recommends shareholders reject “mini-tender” offer by TRC Capital Investment Corporation
Read more
April 4, 2024
Johnson & Johnson to Showcase its Broad Scientific Leadership and Latest Innovations to Combat Cardiovascular Disease at ACC.24
Clinical and real-world evidence presentations highlight how the Company is transforming care for patients who are fighting some of the most common and devastating cardiovascular diseases
Read more
April 3, 2024
Johnson & Johnson Expands Commitment to Advance Health Equity in the United States
Johnson & Johnson supports more than 100 community-led organizations in marginalized communities to provide resources and tools to advance accessible, quality health care in the U.S.
Read more
Load More
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue